In a new study in JAMA Neurology, a team of neuroscientists at Mayo Clinic in Florida led by Melissa Murray, Ph.D., examined a key region of the brain and found that patterns of Alzheimer’s-related damage differed by subtype and age of onset.
The researchers say these observations could have important treatment implications.
Despite many promising leads, more than 120 drug treatments for Alzheimer’s disease have failed. But Cambridge-based biotech company Biogen revived hope on Tuesday with its announcement that it would seek Food and Drug Administration approval for a drug it abandoned earlier this year.
The biotech world went into a full-on frenzy Tuesday when drug giant Biogen dropped this whopper: The company is reviving its Alzheimer’s drug hopeful, aducanumab, after leaving it for dead all the way back in March. In fact, it’s marching forward with a Food and Drug Administration (FDA) application to approve the drug for certain patients facing cognitive decline.
The truth: Alzheimer’s and other dementia diseases are always a burden on loved ones. The lesser-known truth: Dealing with the diseases can provide positive impacts of a temporary or even lasting nature.
Researchers have now found that slower loss of cognitive skills in people with AD correlates with higher levels of a protein that helps immune cells clear plaque-like cellular debris from the brain . The efficiency of this clean-up process in the brain can be measured via fragments of the protein that shed into the cerebrospinal fluid (CSF). This suggests that the protein, called TREM2, and the immune system as a whole, may be promising targets to help fight Alzheimer’s disease.
Hispanics who have trouble sleeping may be at a higher risk of Alzheimer’s disease or other dementias, according to a new study. Read more here: https://www.miamiherald.com/living/health-fitness/article235945087.html#storylink=cpy
The drug company Biogen is asking the FDA to approve one of its Alzheimer’s treatments, a sign that clinical trials have shown success for the therapy. The drug, aducanumab, is still in the experimental stages, and Biogen had thrown in the towel months ago when studies didn’t seem to show progress. The company now says higher doses may be key. An Alzheimer’s drug gaining FDA approval would be blockbuster. There are currently no effective treatments for the memory-robbing disease, which affects more than 5 million people in the U.S. alone
Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have identified a possible treatment for Alzheimer’s disease. Working together with a scientific team at the Rockefeller University in New York, the investigators have shown that treatment with the oral anticoagulant dabigatran delays the appearance of Alzheimer’s disease in mice.
Recognizing and taking steps to address the warning signs of Alzheimer’s and other dementias can be extremely challenging — especially in the early stages. It’s easy and common to dismiss cognitive changes in oneself or a family member as “normal aging.”
Dr. John Morris, a professor of neurology and director of the Knight Alzheimer’s Disease Research Center at Washington University School of Medicine in St. Louis, and Dr. Dennis Selkoe, co-director of the Ann Romney Center for Neurological Disease at Brigham and Women’s Hospital in Boston, agree on some mysteries of Alzheimer’s disease that confound researchers:
here is the punch line: Interventional studies of light to moderate drinking are unfortunately few and far between, therefore the risks of having a glass or two of wine with dinner are poorly understood. It is up to you to carefully consider the risks in your particular case. If you choose to drink red wine, do so because you enjoy it, rather than because of unfounded assertions that it’s good for your brain.
The annual Alzheimer’s Association International Conference (AAIC) shows that the disease progresses differently in women than it does in men. Two thirds of the approximately 5.8 mil-lion Americans living with the disease are women. That’s because women live longer than men, right? Well, that’s long been the assumption, but there’s more to it than that.